Molecular analysis of IDH1/2 mutations and MGMT promoter methylation in gliomas and meningiomas

被引：0
|
作者：
Saetta, A. [1 ]
Gioti, A. [1 ]
Chatziandreou, I. [1 ]
Tsioli, P. [1 ]
Soldatos, R. F. [1 ]
Sakellariou, S. [1 ]
Samaras, V. [1 ]
Sepsa, A. [1 ]
Zisakis, A. [1 ]
Korkolopoulou, P. [1 ]
Patsouris, E. [1 ]
机构：
[1] Univ Athens, Dept Pathol 1, GR-10679 Athens, Greece
来源：
VIRCHOWS ARCHIV | 2013年 / 463卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
引用
收藏
页码：319 / 319
页数：1
相关论文
共 50 条
  • [31] XGBoost Improves Classification of MGMT Promoter Methylation Status in IDH1 Wildtype Glioblastoma
    Le, Nguyen Quoc Khanh
    Do, Duyen Thi
    Chiu, Fang-Ying
    Yapp, Edward Kien Yee
    Yeh, Hui-Yuan
    Chen, Cheng-Yu
    JOURNAL OF PERSONALIZED MEDICINE, 2020, 10 (03): : 1 - 13
  • [32] The association between IDH1 mutation and MGMT promoter methylation in Indonesian glioma patients
    Hudiana, Dina
    Malueka, Rusdy
    Dananjoyo, Kusumo
    Asmedi, Ahmad
    Dwianingsih, Ery Kus
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429
  • [33] THE PROGNOSTIC IMPLICATION OF MGMT PROMOTER METHYLATION IN IDH-MUTANT GLIOMAS
    Youssef, Gilbert
    Aquilanti, Elisa
    Muzikansky, Alona
    Miller, Julie
    Vogelzang, Jayne
    Lapinskas, Emily
    Lim-Fat, Mary Jane
    Rahman, Rifaquat
    Beroukhim, Rameen
    Bi, Wenya Linda
    Chukwueke, Ugonma
    Castro, Luis Nicolas Gonzalez
    Lee, Eudocia
    McFaline-Figueroa, J. Ricardo
    Nayak, Lakshmi
    Reardon, David A.
    Ligon, Keith
    Wen, Patrick Y.
    NEURO-ONCOLOGY, 2022, 24 : 153 - 153
  • [34] IDH1/IDH2 Mutations Define the Prognosis and Molecular Profiles of Patients with Gliomas: A Meta-Analysis
    Zou, Peng
    Xu, Haitao
    Chen, Pin
    Yan, Qing
    Zhao, Lin
    Zhao, Peng
    Gu, Aihua
    PLOS ONE, 2013, 8 (07):
  • [35] The Next Generation of Glioma Biomarkers: MGMT Methylation, BRAF Fusions and IDH1 Mutations
    von Deimling, Andreas
    Korshunov, Andrey
    Hartmann, Christian
    BRAIN PATHOLOGY, 2011, 21 (01) : 74 - 87
  • [36] Expanding the spectrum of IDH1 mutations in gliomas
    Gupta, Ruta
    Flanagan, Simon
    Li, Cheryl C. Y.
    Lee, Maggie
    Shivalingham, Brindha
    Maleki, Sanaz
    Wheeler, Helen R.
    Buckland, Michael E.
    MODERN PATHOLOGY, 2013, 26 (05) : 619 - 625
  • [37] IDH1 and 2 mutations in gliomas from biology to treatment
    Sanson, M.
    Gleize, V.
    de Kerillis, L. Connen
    Di Stefano, A. L.
    Labussiere, M.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S43 - S43
  • [38] IDH1 and IDH2 Mutations in Gliomas, AML, and Intrahepatic Cholangiocarcinoma
    Wachsmann, M. B.
    Hatanpaa, J.
    Chen, W.
    Hammer, S.
    Ram, R.
    Oliver, D.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2017, 19 (06): : 1031 - 1032
  • [39] THE PROGNOSTIC VALUE OF IDH1 MUTATIONS IN GLIOMAS
    Dahlrot, Rikke H.
    Kristensen, Bjarne W.
    Hansen, Steinbjorn
    NEURO-ONCOLOGY, 2011, 13 : 82 - 83
  • [40] Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas
    Killela, Patrick J.
    Pirozzi, Christopher J.
    Healy, Patrick
    Reitman, Zachary J.
    Lipp, Eric
    Rasheed, B. Ahmed
    Yang, Rui
    Diplas, Bill H.
    Wang, Zhaohui
    Greer, Paula K.
    Zhu, Huishan
    Wang, Catherine Y.
    Carpenter, Austin B.
    Friedman, Henry
    Friedman, Allan H.
    Keir, Stephen T.
    He, Jie
    He, Yiping
    McLendon, Roger E.
    Herndon, James E., II
    Yan, Hai
    Bigner, Darell D.
    ONCOTARGET, 2014, 5 (06) : 1515 - 1525
12345